These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30924924)

  • 1. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
    Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
    Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of cerebral drug occupancy in humans using a single PET-scan: A [
    Marstrand-Joergensen MR; Laurell GL; Herrmann S; Nasser A; Johansen A; Lund A; Andersen TL; Knudsen GM; Pinborg LH
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3292-3304. PubMed ID: 38758370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug characteristics derived from kinetic modeling: combined
    Naganawa M; Gallezot JD; Finnema SJ; Maguire RP; Mercier J; Nabulsi NB; Kervyn S; Henry S; Nicolas JM; Huang Y; Chen MK; Hannestad J; Klitgaard H; Stockis A; Carson RE
    EJNMMI Res; 2022 Nov; 12(1):71. PubMed ID: 36346513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.
    Reed RC; Rosenfeld WE; Lippmann SM; Eijkemans RMJC; Kasteleijn-Nolst Trenité DGA
    CNS Drugs; 2020 Oct; 34(10):1075-1086. PubMed ID: 32949370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Sands ZA; Vandenplas C; Gillard M
    Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brivaracetam augments short-term depression and slows vesicle recycling.
    Yang X; Bognar J; He T; Mohammed M; Niespodziany I; Wolff C; Esguerra M; Rothman SM; Dubinsky JM
    Epilepsia; 2015 Dec; 56(12):1899-909. PubMed ID: 26515103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A.
    Yamagata A; Ito K; Suzuki T; Dohmae N; Terada T; Shirouzu M
    Nat Commun; 2024 Apr; 15(1):3027. PubMed ID: 38637505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.
    Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y
    J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M; Fuks B; Leclercq K; Matagne A
    Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brivaracetam exposure-response predictions in pediatric patients from age 1 month: Extrapolation of levetiracetam adult-pediatric scaling to brivaracetam.
    Schoemaker R; Krauwinkel W; Elshoff JP; Stockis A
    Epilepsy Res; 2024 May; 202():107332. PubMed ID: 38518434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy.
    Klein P; Bourikas D
    Adv Ther; 2024 Jul; 41(7):2682-2699. PubMed ID: 38811492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
    Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
    Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.
    Russo E; Citraro R; Mula M
    Expert Opin Drug Discov; 2017 Nov; 12(11):1169-1178. PubMed ID: 28829199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.
    Thomsen MB; Jacobsen J; Lillethorup TP; Schacht AC; Simonsen M; Romero-Ramos M; Brooks DJ; Landau AM
    J Cereb Blood Flow Metab; 2021 Apr; 41(4):819-830. PubMed ID: 32538280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain.
    Warnock GI; Aerts J; Bahri MA; Bretin F; Lemaire C; Giacomelli F; Mievis F; Mestdagh N; Buchanan T; Valade A; Mercier J; Wood M; Gillard M; Seret A; Luxen A; Salmon E; Plenevaux A
    J Nucl Med; 2014 Aug; 55(8):1336-41. PubMed ID: 24935992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous brivaracetam in status epilepticus: A retrospective single-center study.
    Kalss G; Rohracher A; Leitinger M; Pilz G; Novak HF; Neuray C; Kreidenhuber R; Höfler J; Kuchukhidze G; Trinka E
    Epilepsia; 2018 Oct; 59 Suppl 2():228-233. PubMed ID: 30043427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.